Community hub
0 subscribers8 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Procaine.
Nothing was collected or created yet.
Procaine
View on Wikipediafrom Wikipedia
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | Parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | Hydrolysis by plasma esterases |
| Elimination half-life | 40–84 seconds |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.388 |
| Chemical and physical data | |
| Formula | C13H20N2O2 |
| Molar mass | 236.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Procaine is a local anesthetic drug of the amino ester group. It is most commonly used in dental procedures to numb the area around a tooth[1] and is also used to reduce the pain of intramuscular injection of penicillin. Owing to the ubiquity of the trade name Novocain (without the "e" in the original German patent) or Novocaine (with the "e" in the US patent), in some regions, procaine is referred to generically as novocaine. It acts mainly as a sodium channel blocker.[2] Today, it is used therapeutically in some countries due to its sympatholytic, anti-inflammatory, perfusion-enhancing, and mood-enhancing effects.[3]
Procaine was first synthesized in 1905,[4] shortly after amylocaine.[5] It was created by the chemist Alfred Einhorn who gave the chemical the trade name Novocain, from the Latin nov- (meaning "new") and -caine, a common ending for alkaloids used as anesthetics. It was introduced into medical use by surgeon Heinrich Braun.
Prior to the discovery of amylocaine and procaine, cocaine was a commonly used local anesthetic.[6] Einhorn wished his new discovery to be used for amputations, but for this surgeons preferred general anesthesia. Dentists, however, found it very useful.[7]
Pharmacology
[edit].jpg)
The primary use for procaine is as an anaesthetic.
Aside from its use as a dental anesthetic, procaine is used less frequently today, since more effective (and hypoallergenic) alternatives such as lidocaine (Xylocaine) exist. Like other local anesthetics (such as mepivacaine, and prilocaine), procaine is a vasodilator, thus is often coadministered with epinephrine for the purpose of vasoconstriction. Vasoconstriction helps to reduce bleeding, increases the duration and quality of anesthesia, prevents the drug from reaching systemic circulation in large amounts, and overall reduces the amount of anesthetic required.[8] As a dental anesthesic, for example, more novocaine is needed for root canal treatment than for a simple filling.[1] Unlike cocaine, a vasoconstrictor, procaine does not have the euphoric and addictive qualities that put it at risk for abuse.
Procaine is also a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.[9]
Procaine, an ester anesthetic, is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-amino benzoic acid (PABA), which is then excreted by the kidneys into the urine.
A 1% procaine injection has been recommended for the treatment of extravasation complications associated with venipuncture, steroids, and antibiotics. It has likewise been recommended for treatment of inadvertent intra-arterial injections (10 ml of 1% procaine), as it helps relieve pain and vascular spasm.
Procaine is an occasional additive in illicit street drugs and is presented and sold usually as cocaine or heroin.[10]
Adverse effects
[edit]Application of procaine leads to the depression of neuronal activity. The depression causes the nervous system to become hypersensitive, producing restlessness and shaking, leading to minor to severe convulsions.[citation needed] Studies on animals have shown the use of procaine led to the increase of dopamine and serotonin levels in the brain.[11] Other issues may occur because of varying individual tolerance to procaine dosage. Nervousness and dizziness can arise from the excitation of the central nervous system, which may lead to respiratory failure if overdosed. Procaine may also induce weakening of the myocardium, leading to cardiac arrest.[12]
Procaine can also cause allergic reactions causing individuals to have problems with breathing, rashes, and swelling. Allergic reactions to procaine are usually not in response to procaine itself, but to its metabolite PABA. Allergic reactions are in fact quite rare, estimated to have an incidence of 1 per 500,000 injections. About one in 3000 white North Americans is homozygous (i.e. has two copies of the abnormal gene) for the most common atypical form of the enzyme pseudocholinesterase,[13][14] and do not hydrolyze ester anesthetics such as procaine. This results in a prolonged period of high levels of the anesthetic in the blood and increased toxicity.
However, certain populations in the world such as the Vysya community in India commonly have a deficiency of this enzyme.[14]
Synthesis
[edit]Procaine can be synthesized in two ways.
- The first consists of the direct reaction of benzocaine with 2-diethylaminoethanol using sodium ethoxide-ethanol solution as the solvent and base.
- The second is by oxidizing 4-nitrotoluene to 4-nitrobenzoic acid, which is further reacted with thionyl chloride, the resulting acyl chloride is then reacted with 2-diethylaminoethanol to give Nitrocaine. Finally, the nitro group is reduced by hydrogenation over Raney nickel catalyst.
See also
[edit]References
[edit]- ^ a b "How long does numbness last after the dentist?". Medical News Today. May 22, 2018. Retrieved July 14, 2020.
- ^ "Procaine (DB00721)". DrugBank. 2009-06-23.
- ^ Hahn-Godeffroy JD (2011). "Procain-Reset: Ein Therapiekonzept zur Behandlung chronischer Erkrankungen" [Procaine reset: A therapy concept for the treatment of chronic diseases.]. Schweizerische Zeitschrift für Ganzheitsmedizin [Swiss Journal of Integrative Medicine] (in German). 23 (5): 291–6. doi:10.1159/000332021.
- ^ Ritchie JM, Greene NM (1990). "Local Anesthetics". In Gilman AG, Rall TW, Nies AS, Taylor P (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th ed.). New York: Pergamon Press. p. 311. ISBN 0-08-040296-8.
- ^ Minard R (18 October 2006). "The Preparation of the Local Anesthetic, Benzocaine, by an Esterification Reaction" (PDF). Archived from the original (PDF) on 20 July 2011. Retrieved 10 March 2011.
Adapted from Introduction to Organic Laboratory Techniques: A Microscale Approach, Pavia, Lampman, Kriz & Engel, 1989.
- ^ Ruetsch YA, Böni T, Borgeat A (August 2001). "From cocaine to ropivacaine: the history of local anesthetic drugs". Current Topics in Medicinal Chemistry. 1 (3): 175–82. doi:10.2174/1568026013395335. PMID 11895133.
- ^ Drucker P (May 1985). "The discipline of innovation". Harvard Business Review. 3 (3): 68. PMID 10272260.
- ^ Sisk AL (1992). "Vasoconstrictors in local anesthesia for dentistry". Anesthesia Progress. 39 (6): 187–93. PMC 2148619. PMID 8250339.
- ^ Villar-Garea A, Fraga MF, Espada J, Esteller M (2003). "Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells" (PDF). Cancer Research. 63 (16): 4984–9. PMID 12941824.
- ^ "Procaine". ecstasydata.org.
- ^ Sawaki K, Kawaguchi M (November 1989). "Some correlations between procaine-induced convulsions and monoamines in the spinal cord of rats". Japanese Journal of Pharmacology. 51 (3): 369–76. doi:10.1254/jjp.51.369. PMID 2622091.
- ^ "Novocain Official FDA information". drugs.com. August 2007.
- ^ Ombregt L (2013). "Procaine: Principles of Treatment". A System of Orthopaedic Medicine (3rd ed.). Churchill Livingstone. pp. 83–115. doi:10.1016/B978-0-7020-3145-8.00005-3. ISBN 978-0-7020-3145-8.
- ^ a b "Butyrylcholinesterase". OMIM. Retrieved 4 September 2015.
- ^ Einhorn A, Fiedler K, Ladisch C, Uhlfelder E (1909). "Ueber p-Aminobenzoësäurealkaminester". Justus Liebig's Annalen der Chemie. 371 (2): 142–161. doi:10.1002/jlac.19093710204.
- ^ Einhorn A Höchst Ag U.S. patent 812,554; DE 179627, "Verfahren zur Darstellung von p-Aminobenzoësäureaalkaminestern [Method for the prepareation of p-aminobenzoic acid alkamine esters]", published 1906-12-11, assigned to Höchst A.M.; DE 194748, "Verfahren zur Darstellung von p-Aminobenzoësäureaalkaminestern [Method for the prepareation of p-aminobenzoic acid alkamine esters]", published 1908-01-28, assigned to Höchst A.M., addendendum to DE 179627.
Further reading
[edit]- Hahn-Godeffroy JD (2007). "Wirkungen und Nebenwirkungen von Procain: Was ist gesichert?". Komplement Integr. Med. 2: 32–4.
| International | |
|---|---|
| National | |
Procaine
View on Grokipediafrom Grokipedia
Procaine is a synthetic local anesthetic belonging to the aminoester class of drugs, characterized by its chemical formula C₁₃H₂₀N₂O₂ and IUPAC name 2-(diethylamino)ethyl 4-aminobenzoate.[1] Developed as the first non-cocaine-based injectable anesthetic, it functions primarily by reversibly binding to voltage-gated sodium channels in neuronal membranes, thereby inhibiting sodium ion influx and blocking the propagation of nerve impulses to produce localized numbness.[1][2]
Synthesized in 1905 by German chemist Alfred Einhorn, procaine—marketed under the trade name Novocain—was introduced as a safer alternative to cocaine for surgical and dental applications due to its lower toxicity and lack of addictive potential.[2][3] Einhorn's work built on efforts to create ester derivatives of para-aminobenzoic acid (PABA), resulting in a compound with moderate potency, rapid onset, and short duration of action, typically lasting 30 to 60 minutes when used for infiltration or nerve blocks.[2][3] Historically, it revolutionized anesthesia by enabling safer local and regional techniques, including spinal anesthesia, though its use has declined with the advent of more stable aminoamide anesthetics like lidocaine.[4][5]
In clinical practice, procaine hydrochloride is administered via injection for procedures requiring temporary pain relief, such as dental extractions, minor surgeries, and diagnostic nerve blocks, with dosages typically ranging from 1% to 2% solutions up to a maximum of 1,000 mg to avoid systemic toxicity.[2] It exhibits low lipid solubility and a pKa of approximately 8.9, which contributes to its quick metabolism by plasma pseudocholinesterases into PABA and diethylaminoethanol, minimizing prolonged effects but also risking allergic reactions in PABA-sensitive individuals.[3][2] Beyond anesthesia, procaine has demonstrated antiarrhythmic properties by stabilizing cardiac membranes, though this application is rare today.[1]
Adverse effects are primarily dose-dependent and include central nervous system excitation or depression, cardiovascular instability, and methemoglobinemia at high plasma levels, underscoring the need for epinephrine admixture in some formulations to prolong action and reduce absorption rates.[2] Contraindications encompass hypersensitivity to ester anesthetics, certain genetic deficiencies in pseudocholinesterase, and concurrent use with sulfonamides due to PABA interference.[2] Despite its historical significance, procaine's role in modern medicine is limited, serving mainly as a benchmark for local anesthetic development and in resource-constrained settings.[5]
Overview and History
Chemical Identity and Properties
Procaine has the molecular formula CHNO and a molecular weight of 236.31 g/mol.[1] It is an ester-type local anesthetic derived from p-aminobenzoic acid, systematically named 2-(diethylamino)ethyl 4-aminobenzoate according to IUPAC nomenclature.[1][6] The molecular structure features a benzene ring with an amino group (-NH) at the para position and an ester (-COO-) linkage connecting to a 2-(diethylamino)ethyl chain (-CHCHN(CHCH)).[1] In its base form, procaine exists as a white crystalline powder with a melting point of 61°C.[1][6] It exhibits limited solubility in water, approximately 9.45 g/L at 30°C, but is more soluble in alcohol and other organic solvents.[6][7] Procaine has pKa values of 8.9 for the tertiary amine (conjugate acid) and approximately 2.7 for the aromatic amine (conjugate acid).[7][6] Common synonyms include Novocaine, and the clinically used form is procaine hydrochloride, a salt with enhanced water solubility (approximately 1 g per mL).[8] The ester linkage in procaine is susceptible to hydrolysis under alkaline conditions, leading to degradation.[7] To improve stability and solubility, it is typically stored and administered as the hydrochloride salt in cool, dry conditions away from strong bases.[7][8]Discovery and Development
Procaine, the first synthetic local anesthetic, was developed in response to the limitations of cocaine, which had been introduced as a topical anesthetic for ocular surgery by Austrian ophthalmologist Carl Koller in 1884.[9] Cocaine's addictive potential and systemic toxicity prompted the search for safer alternatives, leading German chemist Alfred Einhorn at the University of Munich to synthesize procaine in 1905 as a non-addictive ester derivative of para-aminobenzoic acid.[10][2] Einhorn's work built on earlier efforts to modify cocaine's structure while retaining its anesthetic properties, marking a pivotal shift toward synthetic agents for infiltration and conduction block anesthesia.[11] The compound, initially named procaine and later marketed as Novocain, received its first clinical evaluation in 1905 by surgeon Heinrich Braun, who demonstrated its efficacy for infiltration anesthesia in surgical procedures.[12] Einhorn patented the synthesis process in the United States on February 13, 1906 (U.S. Patent No. 812,554), enabling commercial production by Farbwerke Hoechst.[13] By the 1910s, procaine had gained widespread adoption in dentistry and minor surgery, supplanting cocaine due to its lower toxicity and lack of addiction risk, though its short duration of action limited some applications.[11] Early use revealed challenges, including reports of systemic toxicity from rapid absorption, which prompted refinements such as Braun's addition of epinephrine to local anesthetic solutions—first with cocaine in 1903 and subsequently with procaine in 1905—for vasoconstriction and prolonged effect.[12] These adjustments improved safety for spinal anesthesia, where procaine replaced cocaine by the 1920s, reducing risks of convulsions and cardiovascular collapse associated with the earlier drug.[2] Despite these advances, concerns over ester-linked hypersensitivity persisted, contributing to its gradual decline. In the modern era, procaine has been largely supplanted by amide anesthetics like lidocaine, introduced in 1943 and widely adopted by the late 1940s for superior stability and lower allergy incidence.[2] As a generic drug in 2025, it remains available but with limited production, primarily for niche uses in penicillin combinations and select regional practices where alternatives are unavailable. As of November 2025, formulations such as penicillin G benzathine/penicillin G procaine are on backorder due to manufacturing issues.[14]Clinical Applications
Human Medical Uses
Procaine is primarily indicated for local and regional anesthesia in human medicine, particularly for infiltration anesthesia, peripheral nerve blocks, and dental procedures. It is administered via injection as solutions typically ranging from 0.25% to 2%, with common concentrations of 0.5% to 1% for infiltration and nerve blocks.[2][15] In dental applications, such as tooth extractions and other oral surgeries, procaine—often branded as Novocaine—is injected to provide numbness to the gums and surrounding tissues, allowing painless procedures.[1][16] Administration routes include subcutaneous or intradermal injection for local infiltration, intramuscular or perineural for peripheral nerve blocks, and, historically, intrathecal for spinal anesthesia, though the latter is now rarely used due to associated risks such as transient neurologic symptoms. Typical doses are 1-2 mL of a 1-2% solution per site, with a maximum single-session dose not exceeding 1 g (1000 mg) to avoid toxicity.[2][15] For minor surgical procedures and diagnostic nerve blocks, procaine provides effective short-term analgesia, with onset occurring in 2-5 minutes and duration lasting 30-60 minutes.[15][1] Historically, procaine was combined with penicillin G in intramuscular injections (as procaine penicillin) for the treatment of syphilis during the 1940s and 1950s, offering prolonged antibiotic release while minimizing injection pain.[17] To extend its anesthetic duration, procaine is frequently combined with epinephrine (1:100,000 to 1:200,000), which causes vasoconstriction and reduces systemic absorption.[2] As of 2025, procaine's use in developed countries is limited, largely supplanted by longer-acting amide local anesthetics like lidocaine and articaine in dentistry and surgery due to their superior profiles. However, it remains common in resource-limited settings for its low cost and availability in basic procedures.[18][2]Veterinary and Other Uses
Procaine is widely utilized as a local anesthetic in veterinary medicine for a variety of species, including horses, dogs, and cattle, where it facilitates pain management during procedures such as wound repair, castration, dental interventions, and minor surgeries. In equine practice, it is particularly common for infiltration and regional blocks due to its rapid onset and established availability, often administered via injection or topical sprays to target specific sites. Doses for equines in infiltration anesthesia are typically 25-250 mg total per site, or up to 600-1000 mg depending on procedure and animal size, to achieve effective blockade while minimizing systemic absorption and toxicity risks.[19][20] In food-producing animals like cattle and sheep, procaine is approved for local anesthesia in non-systemic applications, but strict regulatory oversight applies to prevent residue accumulation in edible tissues. The U.S. FDA and equivalent bodies mandate extended withdrawal periods, such as 90 days prior to slaughter and 7 days for milk discard, to ensure food safety; systemic administration is prohibited in these species to avoid potential violations of residue tolerances. As of 2025, procaine's veterinary application has been declining in favor of safer, longer-duration alternatives like bupivacaine, which offer improved efficacy for prolonged procedures with fewer risks of toxicity. Supply shortages have impacted procaine availability in veterinary practice, potentially limiting its use in some regions.[21][22][23] Beyond animal health, procaine has historical significance as a diagnostic tool in allergy testing, particularly through intradermal administration to identify hypersensitivity to ester-type local anesthetics. It continues to play a role in experimental pain management research, where its sodium channel-blocking properties are studied for novel analgesic applications in veterinary and biomedical contexts. Additionally, procaine hydrochloride finds rare niche uses in laboratory and industrial settings as a component of chemical buffers, such as Krebs-Henseleit solution, for maintaining physiological conditions during tissue incubation experiments.[24][1][25]Pharmacology
Mechanism of Action
Procaine exerts its anesthetic effects primarily by acting as a blocker of voltage-gated sodium channels in neuronal membranes. It binds preferentially to the open and inactivated states of these channels, stabilizing the inactivated conformation and thereby preventing the influx of sodium ions necessary for the depolarization phase of the action potential. This inhibition disrupts the propagation of nerve impulses along sensory and motor axons, resulting in reversible loss of sensation and muscle relaxation in the affected area.[2][1][26] The site of action for procaine is primarily extracellular, with the neutral form of the molecule diffusing across the nerve membrane to reach intracellular binding sites within the sodium channel pore. Once bound, it inhibits conduction most effectively in small-diameter, unmyelinated or thinly myelinated fibers, such as C fibers (responsible for dull, aching pain and temperature sensation) and A-delta fibers (mediating sharp, localized pain). Larger myelinated fibers, like A-alpha and A-beta, are less sensitive due to their geometry and higher safety factors for conduction, allowing procaine to selectively target pain pathways at clinically relevant concentrations.[2][6][27] Structurally, procaine's efficacy as a local anesthetic stems from its ester linkage between a para-aminobenzoate moiety and a diethylaminoethanol group, which confers a pKa of approximately 8.9. This relatively high pKa ensures that at physiological pH, a portion exists in the non-ionized form for membrane penetration, while the ionized form predominates intracellularly and contributes to ion trapping in acidic environments, such as inflamed tissues, enhancing local accumulation. As an ester-type anesthetic, procaine is distinguished from amide-type agents (e.g., lidocaine) by its susceptibility to rapid hydrolysis by plasma esterases, leading to a shorter duration of action compared to the more stable, liver-metabolized amides.[27][28] In addition to its primary sodium channel blockade, procaine exhibits mild vasodilatory effects, likely through direct relaxation of vascular smooth muscle, which can increase local blood flow and contribute to faster systemic absorption. It does not significantly interact with GABA receptors or voltage-gated potassium channels at therapeutic concentrations, limiting its effects to sodium-dependent excitability without broader neurotransmitter modulation.[29][30]Pharmacokinetics
Procaine exhibits rapid absorption following local injection, achieving near-complete bioavailability (approximately 100%) at the site of administration due to its direct delivery into tissues.[6] However, systemic absorption is limited by immediate hydrolysis at the injection site, resulting in low plasma concentrations.[2] Topical application leads to slower absorption owing to surface hydrolysis by esterases, though this route is less common for procaine.[3] Distribution of procaine is restricted, with a volume of distribution approximately 0.8 L/kg, reflecting its limited tissue penetration and poor crossing of the blood-brain barrier.[31] Protein binding is low, primarily to plasma proteins, which contributes to its short duration of action. Procaine is rapidly metabolized in plasma by pseudocholinesterase (butyrylcholinesterase) via hydrolysis into p-aminobenzoic acid (PABA) and diethylaminoethanol, with an elimination half-life of approximately 8 minutes in healthy individuals.[33] Genetic variants, such as atypical pseudocholinesterase, can significantly prolong the half-life and effects by reducing enzyme activity.[34] This metabolism links to potential hypersensitivity risks from PABA metabolites. Excretion occurs primarily through the kidneys, with metabolites (including PABA and diethylaminoethanol conjugates) eliminated in urine, accounting for about 80% of the dose within 24 hours; unchanged procaine constitutes less than 2% of urinary output, with no evidence of active renal secretion.[1] Pharmacokinetics of procaine can be altered by certain conditions: liver disease impairs pseudocholinesterase production, extending the half-life and duration of action; pregnancy similarly reduces enzyme levels, potentially prolonging effects; co-administration with epinephrine slows vascular absorption from injection sites, thereby enhancing local anesthetic duration.[36][37][38]Safety and Adverse Effects
Common Adverse Reactions
Procaine, administered as procaine hydrochloride, commonly elicits mild local reactions at the injection site due to its acidic nature, with a pH range of 3.3 to 5.5 for typical solutions. These include transient pain, erythema, and swelling, which arise from the low pH irritating tissues upon infiltration and typically resolve within minutes as the anesthetic takes effect. Such effects are more pronounced with rapid injection and can be mitigated by slowing the administration rate or buffering the solution with sodium bicarbonate to approximate physiological pH, thereby reducing stinging and discomfort.[2][39] Mild systemic reactions, often resulting from rapid absorption into the bloodstream, may manifest as dizziness, headache, or nausea, particularly in procedures involving larger doses or vascular areas. During dental applications, patients may also experience a transient metallic taste in the mouth, attributed to the anesthetic's interaction with oral tissues and sensory nerves. These symptoms are generally self-limiting, occurring in fewer than 5% of administrations, and are more frequent in individuals with heightened sensitivity to injectables, though they do not indicate true allergic responses. Management involves supportive measures such as reassurance and monitoring, with symptoms usually abating spontaneously without intervention.[2][40][41]Serious Risks and Contraindications
Procaine, an ester-type local anesthetic, is associated with type I hypersensitivity reactions stemming from its metabolism to para-aminobenzoic acid (PABA), which can cross-react with sulfonamide antibiotics and PABA-containing sunscreens. These allergic responses occur with an incidence of approximately 0.3-1%, manifesting as urticaria, bronchospasm, or anaphylaxis.[42][43][44] Central nervous system (CNS) toxicity can occur with intravascular injection of doses exceeding 1 g, leading to seizures, coma, and potential respiratory depression. Cardiovascular collapse may also result from procaine-induced vasodilation and direct myocardial depression in severe cases.[2][45] Procaine is contraindicated in individuals with known hypersensitivity to ester local anesthetics, atypical pseudocholinesterase deficiency (which impairs hydrolysis and prolongs effects), and severe liver disease (due to reduced metabolic capacity). It should be used in pregnancy only if clearly needed (FDA Pregnancy Category C).[2][46][47] Overdose management emphasizes supportive measures, including airway protection and seizure control with benzodiazepines. For local anesthetic systemic toxicity (LAST), the American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines, updated as of 2020, recommend intravenous lipid emulsion therapy (20% formulation, initial bolus of 1.5 mL/kg followed by infusion) to mitigate severe cardiac and CNS effects, particularly in at-risk patients where alternatives are preferred.[48][45] Drug interactions that prolong procaine's effects include anticholinesterases like neostigmine, which inhibit plasma pseudocholinesterase responsible for its hydrolysis, potentially leading to extended anesthesia and heightened toxicity risk.[49]Synthesis and Production
Chemical Synthesis
The classic laboratory-scale synthesis of procaine, developed by Alfred Einhorn in 1905, involves a two-step process starting from p-nitrobenzoic acid and 2-diethylaminoethanol.[3] In the first step, p-nitrobenzoic acid is converted to its acid chloride using thionyl chloride, followed by esterification with 2-diethylaminoethanol in a nucleophilic acyl substitution reaction, yielding the intermediate 2-diethylaminoethyl 4-nitrobenzoate (nitrocaine).[3][50] This esterification is typically performed under anhydrous conditions to facilitate the reaction, often in an inert solvent like benzene or toluene. The second step reduces the nitro group to an amine using iron powder in the presence of hydrochloric acid (Fe/HCl), a classic method for selective nitro reduction that avoids affecting the ester linkage.[51][52] The reduction proceeds via formation of iron(II) species that facilitate electron transfer, ultimately producing procaine hydrochloride upon acidification. Overall yields for this route are typically around 70-80% after purification.[53] An alternative laboratory route starts directly from p-aminobenzoic acid, where the amino group is protected as its hydrochloride salt to prevent interference during activation. The protected p-aminobenzoic acid hydrochloride is treated with thionyl chloride to form the acid chloride intermediate at low temperatures (0-5°C) to minimize decomposition.[54] This is followed by nucleophilic addition of 2-diethylaminoethanol at controlled temperatures (0-25°C) in ethanol solvent, promoting selective ester formation while suppressing side reactions such as self-condensation or hydrolysis.[54] Deprotection occurs upon neutralization with base, yielding procaine with an overall efficiency of approximately 70%. This method avoids nitro group handling and is suitable for small-scale synthesis.[3] The key precursor, 2-diethylaminoethanol, is synthesized separately by reacting diethylamine with ethylene chlorohydrin in a nucleophilic substitution, often under basic conditions to neutralize the released HCl and drive the reaction forward.[55] This step uses aqueous or alcoholic media at moderate temperatures (50-80°C) and yields the alcohol in high purity after distillation, ensuring it is free from impurities that could affect downstream esterification. Unlike routes involving cocaine-derived precursors, these syntheses employ readily available, non-controlled starting materials.[51] A modern variant for direct ester coupling employs carbodiimide activation (e.g., dicyclohexylcarbodiimide, DCC) of p-aminobenzoic acid with 2-diethylaminoethanol, forming an O-acylisourea intermediate that undergoes nucleophilic attack by the alcohol to produce the ester without needing acid chloride formation. This method operates under mild, neutral conditions (room temperature in dichloromethane or DMF) and reduces waste from halogenated byproducts, achieving yields comparable to classical routes while minimizing side reactions.[56]Commercial Manufacturing
Commercial manufacturing of procaine hydrochloride primarily involves large-scale esterification followed by catalytic hydrogenation in industrial reactors. The process typically begins with the esterification of p-nitrobenzoic acid with 2-diethylaminoethanol in the presence of a catalyst such as sulfuric acid, conducted in stainless steel reactors under controlled temperature and pressure to yield the nitro ester intermediate.[57] This step is followed by in situ or batch-wise catalytic hydrogenation using hydrogen gas and a metal catalyst like Raney nickel or palladium on carbon, reducing the nitro group to an amino group on a scale of hundreds of kilograms per batch to produce procaine base.[53][58] The use of protected precursors, such as the nitro derivative, prevents side reactions common with the free amino group of p-aminobenzoic acid, ensuring high yields in continuous or semi-continuous operations typical of pharmaceutical API production.[59] Purification occurs post-hydrogenation, where the crude procaine base is dissolved in a solvent like ethanol or water and converted to the hydrochloride salt by addition of hydrochloric acid, followed by recrystallization to achieve pharmaceutical-grade purity.[60] High-performance liquid chromatography (HPLC) is employed for assay and impurity profiling, with United States Pharmacopeia (USP) standards requiring not less than 99.0% and not more than 101.0% purity on a dried basis, including limits on related substances.[61][62] For injectable formulations, Good Manufacturing Practice (GMP) protocols mandate additional sterility testing via membrane filtration and bioburden assessment to meet USP <71> and FDA requirements.[63] Global production of procaine hydrochloride is primarily by generic manufacturers in India and China due to cost-effective raw material access and established API facilities, driven largely by demand for veterinary penicillin combinations and residual human medical uses, though the market remains niche compared to modern anesthetics.[64] USP and FDA standards enforce sterility and endotoxin limits for injectable grades, with certificates of analysis required for international trade.[65] Manufacturing faces challenges from declining demand, as newer local anesthetics like lidocaine supplant procaine, leading to intermittent supply shortages and reduced production incentives for smaller facilities.[23][14] GMP compliance adds complexity, with audits focusing on hydrogenation reactor integrity and impurity controls to prevent batch failures, exacerbating shortages during raw material fluctuations.[66] Environmental management in procaine production addresses waste from hydrogenation steps, where acidic effluents containing nickel catalysts and organic byproducts are neutralized with bases like sodium hydroxide before biological treatment or discharge.[67] Greener alternatives, such as enzymatic reductions, have been explored in pilot studies but remain unadopted at commercial scale due to cost and scalability issues.[68] Overall, wastewater treatment plants at major sites in Asia achieve over 90% removal of procaine residues via ozonation or advanced oxidation to minimize aquatic impacts.[69]References
- https://www.sciencedirect.com/topics/[neuroscience](/page/Neuroscience)/procaine
- https://go.[drugbank](/page/DrugBank).com/drugs/DB00721